10024973DIOS-CoVax clinical trial recruitment and analysisClosedCollaborative R&DInnovate UKVaccines that protect against multiple related viruses have been developed using DIOSynVax technology. This broadly protective approach is needed for the Coronaviruses such as SARS-COV-2 and SARS-COV, two of numerous related viruses that have the potential to cause future outbreaks from zoonotic reservoirs. We have designed antigens to induce an immune response against the Sarbecoviruses in order to protect against the current pandemic and future outbreaks of related Coronaviruses. This vaccine is administered using a needleless technology causing patients' cells to produce the antigens, which are recognized by the immune system to induce protection against SARS-CoV-2 and related Coronaviruses.